Skip to main content

Advertisement

SpringerLink
Log in

A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

This study aimed to explore the effect of bisphosphonate treatment on stroke using a large population cohort study. We found that the patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (hazard ratio (HR) = 0.79; 95% confidence interval (CI) = 0.66–0.99; p = 0.005) during a 2-year follow-up period.

Introduction

Animal models have suggested that bisphosphonates have a beneficial effect on the cardiovascular system. However, data on this topic in human subjects are still lacking. This study aimed to explore the protective effect of bisphosphonate treatment on stroke using a large population cohort study.

Methods

We identified 2,148 patients who received bisphosphonate therapy for osteoporotic fractures. We randomly extracted 6,444 subjects with vertebral or hip fractures as a comparison group matched with the study group on age, sex, and year of index date. Each patient was individually tracked for 2 years to identify those who suffered a stroke. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of stroke.

Results

We found that 184 (8.6%) patients who received bisphosphonate therapy and 696 (10.8%) comparison patients suffered a stroke during the follow-up period. After adjusting for demographic variables and medical co-morbidities, stratified Cox proportional hazards regressions stratified by propensity score revealed that patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (HR = 0.79; 95% CI = 0.66–0.99). The adjusted HR for subarachnoid/intra-cerebral hemorrhage for patients who received bisphosphonate therapy was only 0.53 times (95% CI = 0.33–0.92) that of comparison patients, and the hazard of having an ischemic stroke during the 2-year follow-up period was 0.81 times that of comparison patients (95% CI = 0.65–0.96).

Conclusion

Patients who received bisphosphonate therapy were associated with a lower risk of stroke during a 2-year follow-up period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327:89–95

    Article  PubMed  Google Scholar 

  2. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289

    Article  PubMed  CAS  Google Scholar 

  3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541

    Article  PubMed  CAS  Google Scholar 

  4. Rodan GA, Reszka AA (2002) Bisphosphonate mechanism of action. Curr Mol Med 2:571–577

    Article  PubMed  CAS  Google Scholar 

  5. Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62

    Article  PubMed  CAS  Google Scholar 

  6. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661

    Article  PubMed  CAS  Google Scholar 

  7. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207

    Article  PubMed  CAS  Google Scholar 

  8. Baldini V, Mastropasqua M, Francucci CM, D’Erasmo E (2005) Cardiovascular disease and osteoporosis. J Endocrinol Invest 28:69–72

    PubMed  CAS  Google Scholar 

  9. Burnett JR, Vasikaran SD (2002) Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 39:203–210

    Article  PubMed  CAS  Google Scholar 

  10. Tanko LB, Bagger YZ, Christiansen C (2003) Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73:15–20

    Article  PubMed  CAS  Google Scholar 

  11. Mussolino ME, Madans JH, Gillum RF (2003) Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study. Ann Epidemiol 13:692–697

    Article  PubMed  Google Scholar 

  12. Strandberg TE (2008) Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med 168:2386–2387

    Article  PubMed  Google Scholar 

  13. Watts N (2002) Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J 95:578–582

    PubMed  Google Scholar 

  14. Ylitalo R (2003) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287–296

    Google Scholar 

  15. Fiore CE, Pennisi P, Pulvirenti I, Francucci CM (2009) Bisphosphonates and atherosclerosis. J Endocrinol Invest 32:38–43

    PubMed  CAS  Google Scholar 

  16. Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B (2009) Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 602:124–131

    Article  PubMed  CAS  Google Scholar 

  17. Ylitalo R, Syvala H, Tuohimaa P, Ylitalo P (2002) Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 90:139–143

    Article  PubMed  CAS  Google Scholar 

  18. Ylitalo R, Monkkonen J, Urtti A, Ylitalo P (1996) Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 127:200–206

    Article  PubMed  CAS  Google Scholar 

  19. Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Moorehead TJ, Parmley WW (1994) Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits. Cardiology 85:370–377

    Article  PubMed  CAS  Google Scholar 

  20. Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712–713

    PubMed  CAS  Google Scholar 

  21. Delibasi T, Emral R, Erdogan MF, Kamel N (2007) Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther 24:319–325

    Article  PubMed  CAS  Google Scholar 

  22. Celiloglu M, Aydin Y, Balci P, Kolamaz T (2009) The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689–693

    Article  PubMed  Google Scholar 

  23. Tintut Y, Demer LL (2001) Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 12:555–560

    Article  PubMed  CAS  Google Scholar 

  24. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805–811

    Article  PubMed  Google Scholar 

  25. Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575–584

    Article  PubMed  CAS  Google Scholar 

  26. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21:684–694

    Article  PubMed  Google Scholar 

  27. Fujita H, Utsumi T, Muranaka S, Ogino T, Yano H, Akiyama J, Yasuda T, Utsumi K (2005) Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 69:1773–1784

    Article  PubMed  CAS  Google Scholar 

  28. Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161–1170

    Article  PubMed  CAS  Google Scholar 

  29. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A (2006) Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17:693–703

    Article  PubMed  CAS  Google Scholar 

  30. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826–831

    Article  PubMed  CAS  Google Scholar 

  31. Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813–816

    Article  PubMed  Google Scholar 

  32. John Camm A (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 32:426–443

    Article  PubMed  CAS  Google Scholar 

  33. Sheu JJ, Kang JH, Lou HY, Lin HC (2010) Reflux esophagitis and the risk of stroke in young adults: a 1-year population-based follow-up study. Stroke 41:2033–2037

    Article  PubMed  Google Scholar 

  34. Lin HC, Xirasagar S, Chen CH, Hwang YT (2008) Physician’s case volume of intensive care unit pneumonia admissions and in-hospital mortality. Am J Respir Crit Care Med 177:989–994

    Article  PubMed  Google Scholar 

  35. Wang LH, Lin HC, Lin CC, Chen YH, Lin HC (2010) Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin Pharmacol Ther 88:369–374

    Article  PubMed  CAS  Google Scholar 

  36. Lin HL, Chen YH, Lin HC, Lin HC (2009) No increase in adverse pregnancy outcomes for women receiving antiepileptic drugs. J Neurol 256:1742–1749

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan and managed by the National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or the National Health Research Institutes.

Conflicts of interest

None.

Funding source

None.

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

    J.-H. Kang

  2. School of Medical Laboratory Sciences and Biotechnology, Taipei Medical University, Taipei, Taiwan

    J. J. Keller

  3. School of Health Care Administration, College of Medicine, Taipei Medical University, 250 Wu-Hsing St, Taipei, 110, Taiwan

    H.-C. Lin

Authors
  1. J.-H. Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.-C. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.-C. Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, JH., Keller, J.J. & Lin, HC. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23, 2551–2557 (2012). https://doi.org/10.1007/s00198-012-1894-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-1894-0

Keywords

Search

Navigation